Previous 10 |
The FDA has signed off on Lipocine's ( LPCN -7.6% ) IND for a Phase 2 clinical trial assessing LPCN 1144 in patients with nonalcoholic steatohepatitis (NASH) with fibrosis. Participants in the randomized study will be treated for 36 weeks. More news on: Lipocine Inc., Healthcare stocks...
SALT LAKE CITY , Feb. 14, 2019 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a specialty pharmaceutical company, today announced that the U.S. Food & Drug Administration ("FDA") indicated that the Phase 2 clinical study of LPCN 1144 in non-alcoholic steatohepatitis ("NASH") with ...
Phase I LPCN 1144 Clinical Study Lipocine ( LPCN ) reported the 8-week top line interim result from Liver Fat Study using magnetic resonance imaging, proton density fat fraction (“MRI-PDFF”) technique on January 17, 2019. LPCN 1144 is an oral prodrug that contains bioidentical ...
CORAL GABLES, FL / ACCESSWIRE / January 24, 2019 / The healthcare stock market has become a hotbed of conversation over the course of the past year or so, with headlines on the industry hitting the media on a consistent basis. Companies in the space have tasked their medical experts and pr...
China Lending (NASDAQ: CLDC ) +35% amid investment, business factoring update. More news on: China Lending Corporation, Teligent, Inc., Xilinx, Inc., Stocks on the move, , Read more ...
SALT LAKE CITY , Jan. 24, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced that it has filed an Investigational New Drug application ("IND") with the U.S. Food and Drug Administration ("FDA") to initiate a Phase 2 clinical ...
Lipocine (NASDAQ: LPCN ): EPS of -$0.15 beats by $0.10 . Cash, cash equivalents, and marketable securities of $20.1M Press Release More news on: Lipocine Inc., Earnings news and commentary, ,
SALT LAKE CITY , Aug. 7, 2018 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial results for the three and six months ended June 30, 2018 . Second Quarter and Recent Corporate Highlights Received a Complete ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 02:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study PR Newswire Met standard bioequivalence (BE) criteria C max, AUC 0-t , and AUC 0- ∞ C trough criterion was met LPCN 1154 was well tolerat...
Shares of Lipocine Inc. (NASDAQ: LPCN) traded at a new 52-week high today and are currently trading at $8.96. So far today, approximately 78,318 shares have been exchanged, as compared to an average 30-day volume of 32,701 shares. Lipocine Inc., a clinical-stage biopharmaceutical company, foc...